A Prospective, Multicenter Analysis of Recurrence-Free Survival After Sentinel Lymph Node Biopsy Decisions Influenced by the 31-GEP

IF 3.1 2区医学 Q2 ONCOLOGY Cancer Medicine Pub Date : 2025-04-01 DOI:10.1002/cam4.70839

J. Michael Guenther, Andrew Ward, Brian J. Martin, Mark Cripe, Timothy Beard, Oliver Wisco, Rohit Sharma, Stanley P. Leong, Richard Essner, Joseph I. Clark, John Hamner, Brenda Sickle-Santanello, Maki Yamamoto

{"title":"A Prospective, Multicenter Analysis of Recurrence-Free Survival After Sentinel Lymph Node Biopsy Decisions Influenced by the 31-GEP","authors":"J. Michael Guenther, Andrew Ward, Brian J. Martin, Mark Cripe, Timothy Beard, Oliver Wisco, Rohit Sharma, Stanley P. Leong, Richard Essner, Joseph I. Clark, John Hamner, Brenda Sickle-Santanello, Maki Yamamoto","doi":"10.1002/cam4.70839","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Although most patients with cutaneous melanoma (CM) will have a negative sentinel lymph node biopsy (SLNB), up to 20%–30% of these patients will recur. The 31-gene expression profile (31-GEP) test has been prospectively validated to identify patients at low (Class 1A), intermediate (Class 1B/2A), and high (Class 2B) risk of SLN positivity and recurrence.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>DECIDE is a prospective, multicenter study to assess the effect of 31-GEP testing on SLNB performance rates in patients with T1–T2 tumors considering SLNB and to study long-term outcomes. Here, we assessed outcomes in patients with a Class 1A 31-GEP result (<i>n</i> = 130).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Of Class 1A patients, 63 had an SLNB, with a 3.2% SLN positivity rate (2/63). No Class 1A patients, regardless of SLN status, experienced a recurrence (2-year median follow-up).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>These results are consistent with previous studies that showed the 31-GEP can identify patients at low risk of SLN positivity and recurrence.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 7","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70839","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70839","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Although most patients with cutaneous melanoma (CM) will have a negative sentinel lymph node biopsy (SLNB), up to 20%–30% of these patients will recur. The 31-gene expression profile (31-GEP) test has been prospectively validated to identify patients at low (Class 1A), intermediate (Class 1B/2A), and high (Class 2B) risk of SLN positivity and recurrence.

Methods

DECIDE is a prospective, multicenter study to assess the effect of 31-GEP testing on SLNB performance rates in patients with T1–T2 tumors considering SLNB and to study long-term outcomes. Here, we assessed outcomes in patients with a Class 1A 31-GEP result (n = 130).

Results

Of Class 1A patients, 63 had an SLNB, with a 3.2% SLN positivity rate (2/63). No Class 1A patients, regardless of SLN status, experienced a recurrence (2-year median follow-up).

Conclusions

These results are consistent with previous studies that showed the 31-GEP can identify patients at low risk of SLN positivity and recurrence.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

前哨淋巴结活检决定受31-GEP影响后无复发生存的前瞻性多中心分析

虽然大多数皮肤黑色素瘤（CM）患者前哨淋巴结活检（SLNB）呈阴性，但高达20%-30%的患者会复发。31基因表达谱（31-GEP）测试已被前瞻性验证，用于识别低（1A类）、中（1B/2A类）和高（2B类）SLN阳性和复发风险的患者。方法DECIDE是一项前瞻性、多中心研究，旨在评估31-GEP检测对考虑SLNB的T1-T2肿瘤患者SLNB成形率的影响，并研究长期预后。在这里，我们评估了1A级31-GEP患者的结局（n = 130）。结果1A类患者中，SLNB 63例，SLN阳性率3.2%（2/63）。无论SLN状态如何，没有1A类患者出现复发（中位随访2年）。结论与既往研究一致，31-GEP可以识别SLN阳性和复发风险较低的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.